At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Iron Dextran +1 moredrug
Likely dose
Iron Dextran 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Practical Anemia Bundle for SusTained Blood Recovery (PABST-BR) Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Iron Dextran and Erythropoietin (EPO) for Anemia and Critical Illness. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The purpose of this study is to test a multi-faceted anemia treatment plan to reduce the severity of anemia and to promote hemoglobin and functional recovery in adults who have been in the intensive care unit (ICU).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Critical Illness
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedDec 2021
Primary CompletionMar 2024
Study CompletionNov 2024
TodayJul 2026
First PostedDec 22, 2021
Enrollment StartNov 30, 2021
Primary CompletionMar 4, 2024
Study CompletionNov 26, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.5 years ago
Interventions
Iron Dextrandrug
1000 mg IV
Erythropoietin (EPO)drug
40,000 units subcutaneous